Dendreon (DNDN) Return on Equity ROE from the third quarter 2014 to third quarter 2013 and annually, average high and low, overall ranking from Sep 30 2014 to Sep 30 2013 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Dendreon Corp  (DNDN)

Dendreon's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Dendreon in the third quarter 2014?
Due to the lack of equity, it was not possible to calculate Dendreon Corp's return on equity (ROE) in its third quarter 2014

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2014)
III. Quarter		 (Jun 30 2014)
II. Quarter		 (Mar 31 2014)
I. Quarter		 (Dec 31 2013)
IV. Quarter		 (Sep 30 2013)
III. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -162 -208 -261 -297 -247
Return On Equity (TTM) - - - - -
DNDN's Total Ranking # # # # #
Equity (TTM) in Millions -320 -300 -286 -248 -161
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to DNDN Management Effectiveness >> DNDN's 5 Years Annual ROE >> Compare DNDN ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





DNDN Annual Return On Equity (Dec 31 2013)
2013		 (Dec 31 2012)
2012		 (Dec 31 2011)
2011		 (Dec 31 2008)
2010
Total Equity in Millions -248 35 353 504 0
Y / Y Equity Change - -90.18 % -29.97 % - -
Net Income in Millions -297 -394 -338 -72 0
Y / Y Net Income Change - - - - -
Return On Equity - -1137.17 % -95.79 % -14.23 % -

Back to DNDN Management Effectiveness >> DNDN's 5 Years Annual ROE >> Compare DNDN ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
DNDN's' Return on Equity at Yahoo Finance
DNDN's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for DNDN's Competitors
Subscribers only: Roe for Dendreon's Suppliers
Subscribers only: Return On Equity for DNDN's Customers




Companies with similar Return On Equity at Sep 30 2014, within Healthcare Sector ROE
Arena Pharmaceuticals Inc   140.52 %
Brainstorm Cell Therapeutics inc   133.90 %
Eternity Healthcare Inc.  127.55 %
Aerie Pharmaceuticals Inc   125.13 %
Lifevantage Corp  107.34 %
Icagen, Inc.  99.25 %
Savara Inc   96.20 %
Bluebird Bio Inc   91.55 %
Bausch Health Companies Inc   87.84 %
Mirati Therapeutics Inc   78.88 %
Cymabay Therapeutics Inc   78.80 %
Abbvie Inc   77.93 %
Applied Genetic Technologies Corporation  77.91 %
Cyclo Therapeutics Inc   76.49 %
Evoke Pharma Inc   76.34 %
Seer Inc   74.59 %
Iveric Bio Inc   70.29 %
Gilead Sciences Inc   67.34 %
Bioage Labs Inc   65.34 %
Sophiris Bio Inc.  64.78 %
Sunwin Stevia International Inc.  64.29 %
Epizyme Inc.  61.60 %
Eyepoint Inc   56.78 %
Sonoma Pharmaceuticals Inc   56.46 %
Encompass Health Corporation  54.96 %
Acceleron Pharma inc  54.28 %
Histogen Inc   54.00 %
Filana Therapeutics Inc   50.96 %
Zoetis Inc   47.75 %
Idexx Laboratories Inc  46.53 %

Date modified: 2026-09-08T15:07:44+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.